GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal

Pact Could Be Worth $353m

 
• By Kevin Grogan

Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
300,000 people around the world are born with SCD each year • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas